Abstract:The application of population approaches to drug development is recommended in several US Food and Drug Administration (Fl)A) guidance documents. Population pharmacokinetic (and pharmacodynamic) techniques enable identification of the sources of inter- and intra-individual variability that impinge. upon drug Safety and efficacy. This article briefly discusses the 2-stage approach to the estimation of population pharmacokinetic parameters, which requires serial multiple measurements on each participant, and comprehensively reviews the nonlinear mixed-effects. modelling approach, which can be applied in situations where extensive sampling is not done on all or any of the participants.Certain preliminary information, such as the compartment model used in describing the pharmacokinetics of the drug, is required for a population pharmacokinetic study. The practical design considerations of the location of sampling times, number of samples/participants and the need to sample an individual more than once should be borne in mind. Simulation may be useful for choosing the study design that will best meet study objectives.The objectives of the population pharmacokinetic study can be secondary to the objectives of the primary clinical study lin which case an add-on population pharmacokinetic protocol may be needed) or primary (when a stand-alone protocol is required). Having protocols for population pharmacokinetic studies is an integral part of 'good pharmacometric practice'.Real-time data assembly and analysis permit an ongoing evaluation of site compliance with the study protocol and provide the opportunity to correct violations of study procedures. Adequate policies and procedures should be in place for study blind maintenance. Real-time data assembly creates the opportunity for detecting and correcting errors in concentration-time data, drug administration history and covariate data.Population pharmacokinetic analyses may be undertaken in 3 interwoven steps: exploratory data analysis, model development and model validation (i.e. predictive performance). Documentation for regulatory purposes should include a complete inventory of key runs in the analyses undertaken (with flow diagrams if possible), accompanied by articulation of objectives, assumptions and hypotheses. Use of diagnostic analyses of goodness of fit as evidence of reliability of results is advised. Finally, the use of stability testing or model validation may be warranted to support label claims.The opinions expressed in this article were revised by incorporating comments from various sources and published by the FDA as 'Guidance for Industry: Population Pharmacokinetics' (see the FDA home page http://www.fda.gov for further information).

Model validation and simulation of population pharmacokinetics

Study approach of population pharmacokinetics

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Applications of model simulation in pharmacological fields and the problems of theoretical reliability

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

PBPK modeling and simulation in drug research and development

Population Pharmacokinetics - A Regulatory Perspective

Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs

Population pharmacokinetic model selection assisted by machine learning

The Use of Population Pharmacokinetics in Drug Development

Development of a Physiologically Based Pharmacokinetic (PBPK) Population Model for Chinese Elderly Subjects

A critical review on approaches to generate and validate virtual population for physiologically based pharmacokinetic models: Methodologies, case studies and way forward

A guide to developing population files for physiologically‐based pharmacokinetic modeling in the Simcyp Simulator

A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization

A fully automatic tool for development of population pharmacokinetic models

Simulating realistic patient profiles from pharmacokinetic models by a machine learning postprocessing correction of residual variability

Application of clinical model which consisted of clinician and clinical pharmacists in compliance of patients with Parkinson's disease

Cross-Validation for Nonlinear Mixed Effects Models

Application of machine learning techniques in population pharmacokinetics/pharmacodynamics modeling

Establish the Population Pharmacokinetics Model of Azithromycin in Chinese Healthy Volunteers

Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways